Investment reflects General Proximity's strong scientific position and innovation in next-generation induced proximity medicines, and the interest in a potential future strategic collaboration from Daewoong Pharmaceutical.

投资反映了通用邻近公司在下一代诱导邻近药物方面的强大科学地位和创新能力，以及大熊制药对未来潜在战略协作的兴趣。

SAN FRANCISCO

旧金山

,

，

May 4, 2026

2026年5月4日

/PRNewswire/ -- FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., today announced its investment in General Proximity, a San Francisco-based biotechnology company pioneering the next generation of induced proximity medicines..

/PRNewswire/ -- FreeMind Investments（FMI），由FreeMind集团与大熊制药有限公司合作成立的风险投资基金，今天宣布投资位于旧金山的生物技术公司General Proximity，该公司致力于开发下一代诱导邻近药物。

General Proximity has built the first mechanism-agnostic proximity discovery engine centered on scanning the 'effectome'—the set of effector proteins that can modulate disease causing proteins to control biology and enable the development of highly efficacious proximity therapeutics for targets previously beyond the reach of medicine.

通用接近性公司构建了首个与机制无关的接近性发现引擎，该引擎专注于扫描“效应体组”——即一组能够调节致病蛋白的效应蛋白，以控制生物学过程，并助力开发针对以往医学无法触及靶点的高度有效接近性疗法。

The company has raised over $20 million, secured five 'Golden Ticket' awards from major pharma companies (AbbVie, Servier, Astellas, Ono, Bristol-Myers Squibb), received non-dilutive grants from ARPA-H and the NIH's National Cancer Institute and most recently announced a strategic multi-target collaboration with Daiichi Sankyo applying its proprietary OmniTAC platform to several oncology programs.

该公司已经筹集了超过2000万美元的资金，获得了来自大型制药公司（艾伯维、施维雅、安斯泰来、小野制药、百时美施贵宝）的五个“金票”奖项，获得了ARPA-H和美国国立卫生研究院国家癌症研究所的非稀释性资助，并且最近宣布与第一三共达成一项战略性的多靶点合作，将其专有的OmniTAC平台应用于多个肿瘤学项目。

The company is advancing its own programs across oncology, cardiometabolic disease, neurodegeneration, and longevity..

公司正在推进其在肿瘤学、心脑代谢疾病、神经退行性疾病和长寿领域的项目。

FreeMind Group, founded in 1999, is the leading non-dilutive funding consultancy for life science organizations, having secured over $2 billion for its clients to date and garnering over $100 million annually. FMI leverages this unique vantage point—using the non-dilutive funding review process as a differentiated due diligence tool to identify high-conviction investment candidates early—while also providing investees with pharma deal-making access, including co-development opportunities and entry into the Asian market..

FreeMind集团成立于1999年，是生命科学组织领先的非稀释性融资咨询公司，迄今为止已为其客户筹集超过20亿美元资金，每年获得超过1亿美元。FMI利用这一独特视角——将非稀释性融资审查流程作为差异化的尽职调查工具，及早识别高信念投资候选项目——同时还为被投资者提供制药交易机会，包括共同开发合作以及进入亚洲市场的途径。

Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company developing, manufacturing, and commercializing first-in-class and best-in-class pharmaceuticals across global markets, with strategic partnerships in more than 100 countries. This investment reflects Daewoong Pharmaceutical's strategic interest in General Proximity's platform and its intent to explore a future strategic collaboration..

大熊制药株式会社成立于1945年，是韩国领先的制药公司，在全球市场开发、生产和销售首创新药和同类最佳药物，并与100多个国家建立了战略合作伙伴关系。此项投资反映了大熊制药对General Proximity平台的战略兴趣，并有意探索未来的战略协作。

'FMI was built to translate deep non-dilutive funding intelligence into investment conviction,' said Ram May-Ron, Founder and Managing Partner at FreeMind Investments. 'General Proximity stands out for the quality of its science, the strength of its team, and its potential to unlock new therapeutic options for targets long considered out of reach.'.

“FMI 的成立是为了将深厚的非稀释性资助情报转化为投资信念，”FreeMind Investments 创始人兼管理合伙人 Ram May-Ron 表示。“General Proximity 凭借其科学质量、团队实力以及解锁长期以来被认为无法触及的靶点新治疗选择的潜力而脱颖而出。”

'We see significant strategic potential in General Proximity's induced proximity approach,' said Seongsoo Park, CEO, Daewoong Pharmaceutical Co., Ltd. 'We look forward to building a future strategic collaboration with the General Proximity team.'

“我们看到通用接近公司的诱导接近方法具有显著的战略潜力，”大熊制药株式会社首席执行官朴圣秀表示，“我们期待与通用接近团队建立未来的战略协作。”

'We are excited to welcome FreeMind Investments and Daewoong Pharmaceutical as investors,' said Armand Cognetta, Founder & Chief Executive Officer of General Proximity. 'Their investment conviction and deep expertise in drug discovery validates our scientific approach and the high-impact pipeline we are building.'.

“我们很高兴欢迎FreeMind Investments和Daewoong Pharmaceutical成为我们的投资者，”General Proximity的创始人兼首席执行官阿尔曼·科格内塔表示，“他们在药物发现方面的投资信念和深厚的专业知识验证了我们的科学方法以及我们正在构建的高影响力产品线。”

ABOUT FREEMIND INVESTMENTS (FMI)

关于自由思维投资（FMI）

FreeMind Investments (FMI) is a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., making direct equity investments while leveraging the non-dilutive funding review process to identify promising life science investment opportunities and bridge the biotech startup 'valley of death.'.

FreeMind Investments（FMI）是一家由FreeMind集团与大熊制药株式会社合作成立的风险投资基金，通过直接股权投资，并借助非稀释性融资审查流程，识别具有潜力的生命科学投资机会，帮助生物科技初创企业跨越“死亡之谷”。

ABOUT FREEMIND GROUP

关于FREEMIND集团

Founded in 1999, FreeMind Group is the leading non-dilutive funding consultancy for life science organizations, having helped clients secure over $2 billion in funding to date, garnering over $100 million annually across NIH, DoD, BARDA, NSF, FDA, and private foundations.

FreeMind Group 成立于1999年，是生命科学领域领先的非稀释性融资咨询公司，迄今为止已帮助客户获得超过20亿美元的资助，每年从美国国立卫生研究院 (NIH)、国防部 (DoD)、生物医学高级研究与发展管理局 (BARDA)、国家科学基金会 (NSF)、食品药品监督管理局 (FDA) 以及私人基金会等机构获取超过1亿美元的资金。

ABOUT DAEWOONG PHARMACEUTICAL CO., LTD.

关于大熊制药公司

Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals globally, with in-house R&D capabilities, international operations across Asia and the United States, and strategic partnerships in more than 100 countries worldwide..

成立于1945年的大熊制药株式会社（Daewoong Pharmaceutical Co., Ltd.）是韩国领先的制药公司，致力于全球范围内的药物研发、生产和商业化。公司拥有自主研发能力，在亚洲和美国设有国际业务，并与全球100多个国家建立了战略合作伙伴关系。

ABOUT GENERAL PROXIMITY

关于通用接近性

General Proximity is a biotechnology company advancing next-generation induced proximity medicines. Its proprietary OmniTAC™ platform enables unbiased identification of effector proteins capable of modulating disease-relevant targets, unlocking new opportunities across oncology and other therapeutic areas.

通用接近（General Proximity）是一家生物技术公司，致力于推进下一代诱导接近药物。其专有的 OmniTAC™ 平台能够无偏见地识别能够调节与疾病相关靶点的效应蛋白，从而在肿瘤学和其他治疗领域开辟新的机会。

The company is advancing multiple preclinical programs generated by the OmniTAC™ platform. .

公司正在推进由OmniTAC™平台生成的多个临床前项目。

SOURCE General Proximity

来源 一般接近性

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示